MedTrace Logo

A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade Meningiomas

NCT07613450 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-05-29

No results posted yet for this study

Summary

This is a randomized, controlled, open-label, multicenter, Phase III clinical study designed to compare the efficacy and safety of SYHA1813 versus treatment of investigators' choice in patients with recurrent or progressive high-grade meningioma not amenable to local therapy.

Conditions

  • High Grade Meningioma

Interventions

DRUG

Investigator's Choice Treatment

Investigator's Choice Treatment：bevacizumab, temozolomide or hydroxyurea

DRUG

SYHA1813

SYHA1813 20mg QD

Sponsors & Collaborators

  • Shanghai Runshi Pharmaceutical Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-20
Primary Completion
2029-07-31
Completion
2029-10-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07613450 on ClinicalTrials.gov